Roosdaal, Belgium

Daniel Pipeleers

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Beta-Cell, N.v.. Active years: 2004.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel Pipeleers

Introduction

Daniel Pipeleers is a notable inventor based in Roosdaal, Belgium. He has made significant contributions to the field of medical science, particularly in the treatment of diabetes mellitus. His innovative approach to pancreatic endocrine cell preparation has garnered attention in the scientific community.

Latest Patents

Daniel Pipeleers holds a patent for a method titled "Method for producing preparations of mature and immature pancreatic endocrine cells." This patent outlines a process for preparing mammalian pancreatic endocrine cells, which includes dissociating intact pancreatic tissue into a cell suspension, enriching the suspension for endocrine cells, and removing non-endocrine cells through density centrifugation. This method is crucial for advancing diabetes treatment.

Career Highlights

Throughout his career, Daniel has worked with various companies, including Beta-Cell and Opus NV. His work in these organizations has focused on developing innovative solutions for diabetes management and cell therapy.

Collaborations

Daniel has collaborated with notable professionals in his field, including Karine Hellemans and Zerihun Assefa. These collaborations have contributed to the advancement of research and development in pancreatic cell preparations.

Conclusion

Daniel Pipeleers is a pioneering inventor whose work has the potential to transform diabetes treatment through innovative cell preparation methods. His contributions to the field are invaluable and continue to inspire further research and development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…